Indications
- Prevention of cerebrovascular accidents (CVA) and systemic embolism in adult patients with non-valvular atrial fibrillation and one or more risk factors, such as congestive heart failure, hypertension, age >= 75 years, diabetes, history of stroke or transient ischemic attack. Treatment of deep vein thrombosis (DVT) and pulmonary embolism, and prevention of recurrent DVT and PE in adults.
API
RIVAROXABAN
Therapeutic area
BLOOD AND HEMATOPOIETIC ORGANS
Forms
Coated tablets
Dosage
20 mg
Presentation
B/30
Table
A